Pular para o conteúdo principal
Ranking Invest

HAE - Haemonetics Corporation

Segmento: HealthcareHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 1.21 Bi
Valor de Mercado
$ 4.67 Bi
Sobrepreço (AV)+287.2%
IVR
0.26A companhia vale 0,26 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.10O valuation alternativo equivale a 10% do valor de mercado da companhia.
MLL
0.10O lucro líquido dos controladores em 16 trimestres equivale a 10% do valor de mercado.
Último Balanço Atualizado: 1T2027

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 837.10 Mi

Dívida Líquida

$ 964.82 Mi

L4T

$ 96.29 Mi

MM4T

7.23%

Indicadores Básicos

ROE

11.50%

Índices de Previsibilidade

Receita Líquida

B0.03

Lucro

B0.16

Margem

B0.17

Índices de Tendência

Receita Líquida

B8.61

Lucro

B4.99

Margem

C3.17

Índices de Endividamento

DIV/PAT

1.15

DIV/L4T

10.02

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.